Friday 05 June, 2020, Royal Marsden Hospital London
1-day course: Targeted Treatments for Haematological Cancers
Level: Advanced/expert (Designed for doctors and senior oncology staff working in haematological cancers. Requires some knowledge of immunology.)
Description: This course describes and explains the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments in development for leukaemia, lymphoma and multiple myeloma. New approaches such as epigenetic modifiers and inhibitors of Bcl-2 and B cell receptor signalling are introduced and the possibility of personalised treatment is discussed.
To book, email conferenceteam@rmh.nhs.uk or call: 020 7808 2922
Programme
Key molecular concepts in leukaemia, lymphoma and myeloma
- Unique properties of myeloid and lymphoid cells
- Common chromosome translocations and their consequences
- Key genetic mutations & molecular pathways
Targets & treatments for blood cancers part 1
- Monoclonal antibody technology
- Targeting cell surface (CD) antigens with monoclonal antibody treatments and their derivatives (eg. conjugated antibodies and bi-specific antibodies)
Targets & treatments for blood cancers part 2
- Targeting over-active signalling pathways, including inhibitors of mTOR, NFκB, FLT3, KIT, JAK/STAT, PKC, B Cell Receptor/SYK
Practical exerciseTargets & treatments for blood cancers part 3
- Targeting the cell cycle (Aurora Kinase & Polo-like Kinase inhibitors, CDK inhibitors, PARP inhibitors)
- Targeting cell survival (proteasome inhibitors and Bcl-2 inhibitors)
- Targeting epigenetics (HDAC inhibitors)
Targets & treatments for blood cancers part 4, specific treatments
- Leukaemia: PML/RARα and BCR-ABL inhibitors
- Lymphoma: ALK inhibitors
- Myeloma: thalidomide + derivatives; targeting the tumour microenvironment;logical treatment combinations